Sarıhan, İremÇalışkan, YaşarMirioğlu, ŞafakÖzlük, YaseminSenates, BanuSeyahi, NurhanBaştürk, TanerYıldız, AbdulmecitKılıçaslan, IşinSever, Mehmet Şükrü2024-07-182024-07-182020-08-010041-1337https://doi.org/10.1097/TP.0000000000003043https://journals.lww.com/transplantjournal/fulltext/2020/08000/amyloid_a_amyloidosis_after_renal_transplantation_.32.aspxhttps://hdl.handle.net/11452/43320Background. There are limited data on the outcome of transplant recipients with familial Mediterranean fever (FMF)-associated AA amyloidosis. The aim of the present study is to evaluate demographic, clinical, laboratory, and prognostic characteristics and outcome measures of these patients. Methods. Eighty-one renal transplant recipients with FMF-associated AA amyloidosis (group 1) and propensity score-matched transplant recipients (group 2, n = 81) with nonamyloidosis etiologies were evaluated in this retrospective, multicenter study. Recurrence of AA amyloidosis was diagnosed in 21 patients (group 1a), and their features were compared with 21 propensity score-matched recipients with FMF amyloidosis with no laboratory signs of recurrence (group 1b). Results. The risk of overall allograft loss was higher in group 1 compared with group 2 (25 [30.9%] versus 12 [14.8%];P= 0.015 [hazard ratio, 2.083; 95% confidence interval, 1.126-3.856]). Patients in group 1 were characterized by an increased risk of mortality compared with group 2 (11 [13.6%] versus 0%;P= 0.001 [hazard ratio, 1.136; 95% confidence interval, 1.058-1.207]). Kaplan-Meier analysis revealed that 5- and 10-year patient survival rates in group 1 (92.5% and 70.4%) were significantly lower than in group 2 (100% and 100%;P= 0.026 andP= 0.023, respectively). Although not reaching significance, overall, 5- and 10-year graft survival rates (57.1%, 94.7%, and 53.8%, respectively) in group 1a were worse than in group 1b (76.2%, 95%, and 77.8%, respectively;P= 0.19,P= 0.95, andP= 0.27, respectively). Conclusions. AA amyloidosis is associated with higher risk of mortality after kidney transplantation. Inflammatory indicators should be monitored closely, and persistent high levels of acute-phase reactants should raise concerns about amyloid recurrence in allograft.eninfo:eu-repo/semantics/closedAccessFamilial mediterranean feverKidney-transplantationOutcomesSurvivalScience & technologyLife sciences & biomedicineImmunologySurgeryTransplantationArticle00056276200003817031711104810.1097/TP.00000000000030431534-6080